nonalcoholic steatohepatitis

Statins for MAFLD/MASH: another brick in the wall while waiting for final answers
Jaime Bosch

Gut Sep 2024, gutjnl-2024-333426; DOI: 10.1136/gutjnl-2024-333426
Epidemiology of gastrointestinal cancers: a systematic analysis from the Global Burden of Disease Study 2021
Pojsakorn Danpanichkul, Kanokphong Suparan, Primrose Tothanarungroj, Disatorn Dejvajara, Krittameth Rakwong, Yanfang Pang, Romelia Barba, Jerapas Thongpiya, Michael B Fallon, Denise Harnois, Rashid N Lui, Michael B Wallace, Ju Dong Yang, Lewis R Roberts, Karn Wijarnpreecha

Gut Sep 2024, gutjnl-2024-333227; DOI: 10.1136/gutjnl-2024-333227
Artificial intelligence applied to ‘omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment
Soumita Ghosh, Xun Zhao, Mouaid Alim, Michael Brudno, Mamatha Bhat

Gut Aug 2024, gutjnl-2023-331740; DOI: 10.1136/gutjnl-2023-331740
Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis
Alessandro Mantovani, Alessandro Csermely, Josh Bilson, Niccolò Borella, Scoccia Enrico, Barbara Pecoraro, Emigela Shtembari, Riccardo Morandin, Stergios A Polyzos, Luca Valenti, Herbert Tilg, Christopher D Byrne, Giovanni Targher

Gut Sep 2024, 73 (9) 1554-1561; DOI: 10.1136/gutjnl-2024-332491
Nuclear receptors: pathophysiological mechanisms and drug targets in liver disease
Vanessa Dubois, Philippe Lefebvre, Bart Staels, Jerome Eeckhoute

Gut Sep 2024, 73 (9) 1562-1569; DOI: 10.1136/gutjnl-2023-331741
Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA
Alexander H Yang, Monica A Tincopa, Federica Tavaglione, Veeral H Ajmera, Lisa M Richards, Maral Amangurbanova, Christian Butcher, Christie Hernandez, Egbert Madamba, Seema Singh, Ricki Bettencourt, Bernd Schnabl, Claude B Sirlin, Rohit Loomba

Gut Aug 2024, gutjnl-2024-332917; DOI: 10.1136/gutjnl-2024-332917
Unravelling the obesity paradox in MASLD patients with extrahepatic cancer
Wenjie Li, Wei Wang

Gut Jul 2024, gutjnl-2024-333087; DOI: 10.1136/gutjnl-2024-333087
FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials
Alessandro Mantovani, Herbert Tilg, Giovanni Targher

Gut Aug 2024, 73 (8) 1400-1402; DOI: 10.1136/gutjnl-2023-331115
MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH
Rohit Loomba, Maral Amangurbanova, Ricki Bettencourt, Egbert Madamba, Harris Siddiqi, Lisa Richards, Cynthia Behling, Claude B Sirlin, Mildred D Gottwald, Shibao Feng, Maya Margalit, Daniel Q Huang

Gut Aug 2024, 73 (8) 1343-1349; DOI: 10.1136/gutjnl-2023-331401
Heavy arch: from inflammatory bowel diseases to metabolic disorders
Timon E Adolph, Moritz Meyer, Almina Jukic, Herbert Tilg

Gut Aug 2024, 73 (8) 1376-1387; DOI: 10.1136/gutjnl-2024-331914

Main menu

nonalcoholic steatohepatitis

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

nonalcoholic steatohepatitis

Pages